|
KMID : 1009020130110010001
|
|
Clinical Psychopharmacology and Neuroscience
2013 Volume.11 No. 1 p.1 ~ p.6
|
|
|
Long-acting Injectable Antipsychotics in First-episode Schizophrenia
|
|
Jeong Hyun-Ghang
Lee Moon-Soo
|
|
|
Abstract
|
|
|
Antipsychotic medications are important for the successful management of schizophrenia. Continuous treatment with medication is superior in relapse prevention and non-adherence to antipsychotic medication is associated with a poor clinical outcome. Long-acting injectable antipsychotics (LAIs) that can guarantee adherence to a treatment regimen could be a useful treatment option. With the introduction of second-generation atypical antipsychotics-long acting injection (SGA-LAI), the risks for extrapyramidal adverse events are decreased. The indications for SGA-LAI have been extended from chronic, stabilized patients to acute psychotic patients. Some studies investigated the use of LAI in first-episode schizophrenia patients and raised the possibility of prescribing LAI as a treatment option. However, there is still limited research using LAI in first-episode schizophrenia. More well-designed, randomized, controlled clinical trials using SGA-LAIs in first episode schizophrenia are needed. Additionally, studies on side effects of SGA-LAI in long-term use are required prior to recommending LAI for patients with first episode
schizophrenia.
|
|
|
KEYWORD
|
|
|
Antipsychotic agents, Injections, Schizophrenia, Delayed-action preparations
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|